CNS Pharma: Surges on FDA nod to start mid-stage brain cancer drug trial

CNS Pharmaceuticals

17/12/2020 15:34

** Shares of biotech co  CNSP.O  jump 26.2% to $2.7 in
morning trade, on course for best day in eight months
    ** Says FDA has approved Investigational New Drug (IND)
application for its brain cancer drug candidate, Berubicin
 urn:newsml:reuters.com:*:nPn1KGSZVa
    ** CNSP expects to start phase 2 trial for Bercubin in Q1
2021
    ** Trial to investigate efficacy of Berubicin in adults with
Glioblastoma Multiforme who have failed first-line therapy
    ** Stock down ~31% so far this year     

 (Reporting by Shivani Kumaresan in Bengaluru)
 ((Shivani.Kumaresan@thomsonreuters.com ; +1 646 223 8780))